Programs

Surrozen is developing a broad pipeline of disease-specific antibodies to help gravely ill patients across multiple disease areas.

Our strategy is to harness the full breadth of Wnt potential by identifying disease states responsive to Wnt pathway modulation, design tissue-specific antibodies, and advance candidates into clinical development in indications with high unmet need.

The following table highlights our lead programs.

* Strategic collaboration with Boehringer Ingelheim


By leveraging our scientific capabilities and approach, we have identified multiple potential tissue types to explore. Our research efforts are currently focused on developing potential therapeutics for diseases of the eye and lung.

Surrozen’s novel approach to modulating the Wnt pathway may lead to therapeutics that reverse the effects of serious diseases by repairing damaged tissue, restoring organ function and renewing a patient’s health, and hope, for an improved quality of life.

Repair. Restore. Renew.